Loading…
← CockpitCompetitor Analysis › 603127.SS Joinn Laboratories (China) Co., Ltd. Class AOpen in the cockpit ↗

Joinn Laboratories (China) Co., Ltd. Class A603127.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Biotechnology

Chinese contract research organization providing preclinical safety and toxicology testing for drug developers.

≈ A Chinese Charles River LaboratoriesMomentum weak 38
Mkt cap
$3.67B
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$225M
20-day average traded
Fwd P/E
29.4×
forward earnings
ROIC−WACC
-10.6 pp
WACC 11.2%
Hurdle
n/a
no reverse DCF
Next earnings
134 days
1 Apr 2027
Close · CNYCN¥37.56
1D-7.9%
1W-18.7%
1M-24.3%
3M-27.6%
6M-6.0%
YTD+7.3%
1Y+9.1%
ATR %8.7%
52w lowhigh32.5% off high

What Joinn Laboratories (China) does

Chinese contract research organization providing preclinical safety and toxicology testing for drug developers.

Charges a fee per study run on a drug developer's behalf, such as safety and toxicology tests in animals, so income follows how many drug programmes its clients start and how well biotech funding holds up. Supply from its own primate colony helps secure capacity for the tests that need it.

In one line: A Chinese Charles River Laboratories.

Products and services

  • Preclinical toxicology/safety testing
  • Non-human primate research models
  • Bioanalysis services

Customers

  • Domestic and multinational biopharma companies

Where it sits in the supply chain

  • Health Care
  • Pharma services
  • Preclinical CRO

What could go right

  • Rising global biotech preclinical outsourcing
  • China biotech pipeline growth

What could go wrong

  • US biosecurity/export-control scrutiny of China CROs
  • Biotech funding cyclicality

Moat: narrow (scale, regulatory licence, installed base). Large non-human-primate colony and GLP-certified labs are costly and slow for rivals to replicate.

Headquarters: Beijing, China · Employees: 2,649

Named competitors

Joinn Laboratories (China) at a glance

Size Joinn Laboratories (China) (603127.SS) is a China Health Care company (Biotechnology) with a market value of $3.67B, the 653rd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥37.56 on 18 Nov 2026.

Performance Over six months the shares fell 6.0%, against +1.1% for the median peer and -20.0% for the China market (cap-weighted) — 9th lowest of 21 in its peer set.

Growth Revenue grew 11.5% over the last twelve months (peer median +6.3%); the operating margin is -3.8% (peer median -1.0%).

Valuation It trades at 29.4× forward earnings against a peer median of 28.5× (5th cheapest of 9).

Capital Return on invested capital runs 10.6 points below its cost of capital (11.2% WACC).

Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026Peer median 101603127.SS 96
Six months, rebased to 100: Joinn Laboratories (China) against the median of its 20 peers (local-currency closes).

Joinn Laboratories (China) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.86BCN¥1.66BCN¥2.02BCN¥2.38BCN¥2.26B
Revenue growth—-18%-15%+6%—
Gross profitCN¥546MCN¥302MCN¥532MCN¥986MCN¥1.04B
EBITDAn/aCN¥33.9MCN¥218MCN¥718MCN¥824M
Net incomeCN¥1.15BCN¥298MCN¥74.1MCN¥397MCN¥1.07B
Free cash flowCN¥649MCN¥376MCN¥264MCN¥455MCN¥738M
Capital expenditureCN¥453MCN¥144MCN¥269MCN¥193MCN¥275M
Total debtCN¥37.1MCN¥21.6MCN¥61.0MCN¥85.8MCN¥120M

Quarterly statements and history in the cockpit →

Joinn Laboratories (China) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%RLAYTNGXABCLIRON600161IOVACRSP66966919ELVN603392002007VIRPXERSADMATLX000661EWTX603127.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Joinn Laboratories (China) is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×600161002007VIRP1530XERSADMATLX000661603127.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Joinn Laboratories (China) is the large dot.

Joinn Laboratories (China) competitors and peer comparison

Head to head with its named competitors (603127.SS vs CRL vs 2359.HK vs 3759.HK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Joinn Laboratories (China) 603127.SS$3.67B-6%+12%-4%29.4×n/a
Charles River Laboratories CRL$16.0B+114%-1%15%26.2×25.6%
Wuxi Apptec 2359.HK$64.1B+51%+38%44%19.5×8.4%
Pharmaron Beijing 3759.HK$9.65B+48%+24%14%20.8×n/a

How Joinn Laboratories (China) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Joinn Laboratories (China) against its 20 peers (data as of 18 Nov 2026)
Measure603127.SSPeer medianRank in peer set
1-month return-24.3%-4.9%2nd lowest of 21
6-month return-6.0%+1.1%9th lowest of 21
Distance from 52-week high-32.5%-31.1%10th lowest of 21
Revenue growth (TTM)+11.5%+6.3%7th highest of 16
Operating margin-3.8%-1.0%7th lowest of 15
Forward P/E29.4×28.5×5th cheapest of 9
ROIC minus cost of capital-10.6 pp-8.2 pp6th lowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Joinn Laboratories (China) 603127.SSChina$3.67B-6%+12%-4%29.4×n/an/a
Relay Therapeutics RLAYUnited States$3.65B+27%+24%-3,095%n/an/an/a
Tango Therapeutics TNGXUnited States$3.71B+4%-100%n/an/an/an/a
AbCellera Biologics ABCLUnited States$3.60B+141%+92%-298%n/an/an/a
Disc Medicine IRONUnited States$3.55B+16%n/an/an/an/an/a
Beijing Tiantan Biological Products 600161.SSChina$3.47B-13%-13%21%33.1×2.2%+12.5%
Iovance Biotherapeutics IOVAUnited States$3.46B+111%+51%-61%n/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%n/an/an/a
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
Caliway Biopharmaceuticals 6919.TWTaiwan$3.32B-25%-54%-6,983%n/an/an/a
Enliven Therapeutics ELVNUnited States$3.30B+7%n/an/an/an/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%n/an/an/a
Hualan Biological Engineering 002007.SZChina$3.20B-17%-11%17%26.7×15.8%-1.8%
Virbac VIRP.PAFrance$3.20B-4%+4%15%16.6×5.8%+9.4%
3SBio 1530.HKHong Kong$4.28B-31%+102%61%12.0×n/an/a
Xeris Biopharma XERSUnited States$3.10B+173%+38%13%49.7×29.5%+70.2%
ADMA Biologics ADMAUnited States$3.01B+58%+6%45%16.7×-0.8%+64.6%
Telix Pharmaceuticals TLX.AXAustralia$2.99B-2%+27%-1%34.5×n/an/a
Dyne Therapeutics DYNUnited States$2.97B-10%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%30.3×32.4%+7.1%
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a

Questions

Who are Joinn Laboratories (China)'s main competitors?
Named competitors: Charles River Laboratories (CRL), WuXi AppTec (2359.HK), Pharmaron Beijing (3759.HK). The cockpit's measured peer set (industry) also includes Relay Therapeutics (RLAY), Tango Therapeutics (TNGX), AbCellera Biologics (ABCL), Disc Medicine (IRON), Beijing Tiantan Biological Products (600161.SS), Iovance Biotherapeutics (IOVA).
Is Joinn Laboratories (China) expensive compared with its peers?
On forward p/e it trades at 29.4× against a peer median of 28.5×, 5th cheapest of 9 in its peer set.
How has Joinn Laboratories (China) stock performed?
Over six months to 18 Nov 2026 the shares returned -6.0% against +1.1% for the median peer; over one year +9.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.